© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure
Montreal Heart Institute, Research Center and Department of Medicine, 5000 Belanger Street East, Montreal, HlT 1C8 Quebec, Canada
* Corresponding author. Tel.: +1-514-376-3330x3564; fax: +1-514-593-2500 tardifjc{at}icm.umontreal.ca
Objective: Atrial remodeling contributes to the maintenance of atrial fibrillation (AF) in several cardiac disorders. There is evidence that angiotensin-converting enzyme (ACE) inhibitors reduce the prevalence of AF in patients with congestive heart failure (CHF). There have been no studies performed to assess the effects of ACE inhibitors on atrial dimensions and emptying function in relationship to vulnerability to AF in the setting of experimental CHF. Methods: CHF was produced in 20 dogs by rapid right ventricular pacing during 5 weeks. The dogs were randomized to enalapril (EN) therapy (2 mg/kg/day, n=10) or to a control group (n=10). Echocardiography was performed at baseline and weekly thereafter. At the 5-week electrophysiological study, AF was induced by burst pacing and AF duration was measured. Results: Atrial areas increased significantly with CHF. Left atrial (LA) fractional area shortening (FAS) decreased by 42% (P=0.0001) in controls but by 9% (P=NS) in the EN group (P=0.01, EN vs. controls). Similar findings were observed for right atrial (RA) changes (P=0.02). Atrial fibrosis was highly correlated with the decrease in LA FAS (r=0.85, P<0.01) and was reduced by EN (from 11.2±1.6 to 8.3±0.7%, P=0.008). AF duration was 720±461 s for controls and 138±83 s for EN (P=0.001). LA and RA areas and FAS at 5 weeks correlated with AF duration (P
0.001 for all). FAS decrease in both atria also correlated with AF duration at follow-up (r=0.78 and 0.77 for LA and RA, P0.001 for both). Conclusions: Experimental CHF causes structural and functional abnormalities in both atria, which are correlated with AF duration. ACE inhibition attenuates CHF-induced atrial fibrosis and remodeling and reduces associated AF promotion. These results indicate a role for the renin–angiotensin system in arrhythmogenic atrial structural remodeling in CHF.
KEYWORDS ACE inhibitors; Arrhythmia (mechanisms); Atrial function; Fibrosis; Heart failure; Remodeling; Supraventr. arrhythmia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Sridhar, Y. Nishijima, D. Terentyev, M. Khan, R. Terentyeva, R. L. Hamlin, T. Nakayama, S. Gyorke, A. J. Cardounel, and C. A. Carnes Chronic heart failure and the substrate for atrial fibrillation Cardiovasc Res, November 1, 2009; 84(2): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Anter and D. J. Callans Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort Circulation, October 6, 2009; 120(14): 1436 - 1443. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Rennison and D. R. Van Wagoner Impact of Dietary Fatty Acids on Cardiac Arrhythmogenesis Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 460 - 469. [Full Text] [PDF]
|
|
|
|
 |
|
 The GISSI-AF Investigators Valsartan for Prevention of Recurrent Atrial Fibrillation N. Engl. J. Med., April 16, 2009; 360(16): 1606 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson Fibrillatory rate response to candesartan in persistent atrial fibrillation Europace, October 1, 2008; 10(10): 1138 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rusinaru, L. Leborgne, M. Peltier, and C. Tribouilloy Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction Eur J Heart Fail, June 1, 2008; 10(6): 566 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Burstein and S. Nattel Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 802 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Shang, S. Sanyal, A. E. Pfahnl, Z. Jiao, J. Allen, H. Liu, and S. C. Dudley Jr. NF-{kappa}B-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II Am J Physiol Cell Physiol, January 1, 2008; 294(1): C372 - C379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Laurent, G. Moe, X. Hu, B. Holub, H. Leong-Poi, J. Trogadis, K. Connelly, D. Courtman, B. H. Strauss, and P. Dorian Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model Cardiovasc Res, January 1, 2008; 77(1): 89 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif and M. Talajic Perindopril and prevention of atrial fibrillation Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E25 - E29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Van Gelder Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue Cardiovasc Res, April 1, 2007; 74(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 C. I Coleman, S. Makanji, J. Kluger, and C M. White Effect of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on the Frequency of Post-Cardiothoracic Surgery Atrial Fibrillation Ann. Pharmacother., March 1, 2007; 41(3): 433 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dagres, G. Karatasakis, F. Panou, G. Athanassopoulos, T. Maounis, E. Tsougos, K. Kourea, I. Malakos, D. Th. Kremastinos, and D. V. Cokkinos Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation Eur. Heart J., September 1, 2006; 27(17): 2062 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Ellinor, A. F. Low, and C. A. MacRae Reduced apelin levels in lone atrial fibrillation Eur. Heart J., January 2, 2006; 27(2): 222 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kalus, C. I. Coleman, and C. M. White The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation J. Clin. Pharmacol., January 1, 2006; 46(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Milliez, N. DeAngelis, C. Rucker-Martin, A. Leenhardt, E. Vicaut, E. Robidel, P. Beaufils, C. Delcayre, and S. N. Hatem Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction Eur. Heart J., October 2, 2005; 26(20): 2193 - 2199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Dudley Jr, N. E. Hoch, L. A. McCann, C. Honeycutt, L. Diamandopoulos, T. Fukai, D. G. Harrison, S. I. Dikalov, and J. Langberg Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases Circulation, August 30, 2005; 112(9): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Healey, A. Baranchuk, E. Crystal, C. A. Morillo, M. Garfinkle, S. Yusuf, and S. J. Connolly Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1832 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1243 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif, P. L. L'Allier, P.-F. Keller, and A. Ducharme Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: A possible contributing mechanism: Reply J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1144 - 1144. [Full Text] [PDF]
|
|
|
|
|
|
K. Wachtell, M. Lehto, E. Gerdts, M. H. Olsen, B. Hornestam, B. Dahlof, H. Ibsen, S. Julius, S. E. Kjeldsen, L. H. Lindholm, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study J. Am. Coll. Cardiol., March 1, 2005; 45(5): 712 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Williams, D. T. Connelly, M. Jackson, A. Bennett, K. Albouaini, and D. M. Todd Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation? Europace, January 1, 2005; 7(6): 554 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wasson, H. K. Reddy, and M. L. Dohrmann Current Perspectives of Electrical Remodeling and Its Therapeutic Implications Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 129 - 144. [Abstract] [PDF]
|
|
|
|
|
|
J. Xu, G. Cui, F. Esmailian, M. Plunkett, D. Marelli, A. Ardehali, J. Odim, H. Laks, and L. Sen Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation Circulation, January 27, 2004; 109(3): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Ueng, T.-P. Tsai, W.-C. Yu, C.-F. Tsai, M.-C. Lin, K.-C. Chan, C.-Y. Chen, D.-J. Wu, C.-S. Lin, and S.-A. Chen Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study Eur. Heart J., December 1, 2003; 24(23): 2090 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Boldt, U. Wetzel, J. Weigl, J. Garbade, J. Lauschke, G. Hindricks, H. Kottkamp, J. F. Gummert, and S. Dhein Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Boixel, V. Fontaine, C. Rucker-Martin, P. Milliez, L. Louedec, J.-B. Michel, M.-P. Jacob, and S. N. Hatem Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat J. Am. Coll. Cardiol., July 16, 2003; 42(2): 336 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kumagai, H. Nakashima, H. Urata, N. Gondo, K. Arakawa, and K. Saku Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2197 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vermes, J.-C. Tardif, M. G. Bourassa, N. Racine, S. Levesque, M. White, P. G. Guerra, and A. Ducharme Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials Circulation, June 17, 2003; 107(23): 2926 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Gronefeld and S. H. Hohnloser Heart Failure Complicated by Atrial Fibrillation: Mechanistic, Prognostic, and Therapeutic Implications Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 107 - 113. [Abstract] [PDF]
|
|
|
|
|
|
S. Nattel, M. Allessie, and M. Haissaguerre Spotlight on atrial fibrillation--the 'complete arrhythmia' Cardiovasc Res, May 1, 2002; 54(2): 197 - 203. [Full Text] [PDF]
|
|